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Common Variants of Large Effect
in F12, KNG1, and HRG Are Associated
with Activated Partial Thromboplastin Time
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Gordon D. Lowe,5 Peter M. Visscher,6,8 and Ian J. Deary1,8,*
Activated partial thromboplastin time (aPTT) is associated with risk of thrombosis and coagulation disorders. We conducted a genome-
wide association study for aPTT and identiﬁed signiﬁcant associations with SNPs in three coagulation cascade genes, F12 (rs2731672,
combined p¼ 2.163 1030), KNG1 (rs710446, combined p¼ 9.523 1022), andHRG (rs9898, combined p¼ 1.343 1011). These three
SNPs explain ~18% of phenotypic variance in aPTT in the Lothian Birth Cohorts.Thrombotic disorders are among the most common causes
of morbidity and mortality in the western world.1 Epide-
miological studies show that shortening of the activated
partial thromboplastin time (aPTT) is not only associated
with several prothrombotic risk factors, including age,
female sex, estrogen use, and obesity,2 but also increased
risk of thrombosis.3 Prolonged aPTT is an indicator of coag-
ulation disorders in patients with deﬁciencies of factors
in the intrinsic pathway of coagulation. As a result, aPTT
is considered a global test of thrombotic tendency. There
is high heritability for variation in aPTT4,5 and risk of
thrombosis,6 indicating the importance of genetic effects
in the normal quantitative variation of aPTT.
We aimed to identify polymorphisms causing variation
in aPTT in the general older population via genome-
wide association methods in a total of 1477 adults from
the Lothian Birth Cohorts of 1936 (LBC1936) and 1921
(LBC1921). The LBC1936 consists of 1091 relatively
healthy individuals assessed on cognitive and medical
traits at 70 years of age.7 They were born in 1936, most
took part in the Scottish Mental Survey of 1947, and
almost all lived independently in the Lothian region (Edin-
burgh city and surrounding area) of Scotland. The sample
of 548 men and 543 women had a mean age of 69.6 years
(standard deviation [SD]¼ 0.8). A full description of partic-
ipant recruitment and testing can be found elsewhere.7,8
The LBC1921 cohort consists of 550 relatively healthy
individuals, 316 females and 234 males, assessed on cogni-
tive andmedical traits at 79 years of age. They were born in
1921, most took part in the Scottish Mental Survey of
1932, and almost all lived independently in the Lothian
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pant recruitment and testing can be found elsewhere.8
Ethics permission for the study was obtained from the
Multi-Centre Research Ethics Committee for Scotland
(MREC/01/0/56) and from Lothian Research Ethics Com-
mittee (LBC1936: LREC/2003/2/29 and LBC1921: LREC/
1998/4/183). The research was carried out in compliance
with the Helsinki Declaration. All subjects gave written,
informed consent.
Blood samples were drawn from participants in both
cohorts via the same protocol. Blood samples were sent
for processing immediately, and the clotting tests were per-
formed upon receipt. aPTT was measured in an ACL-Top
Haemostasis testing system (Instrumentation Laboratory)
with the SynthASil kit (HemosIL, Instrumentation Labora-
tory), the reliability of which is very high (coefﬁcient of
variation ¼ 1.6%). Here we report the aPTT ratio for
both cohorts. This is the ratio of the patient’s aPTT to the
aPTT reference value of the laboratory, herein referred
to as aPTT. We have aPTT measurements available for
LBC1936, which correlates almost perfectly (R2 ¼ 0.95)
with the aPTT ratio.
Genotyping was performed with the Illumina
Human610-Quadv1 chip; 542,050 SNPs passed quality
control. Of the 1091 individuals in the LBC1936, genomic
DNA was isolated from 1071 by standard procedure at
the Wellcome Trust Clinical Research Facility (WTCRF)
Genetics Core. Twenty-nine samples failed quality control
preceding the genotyping procedure. The remaining 1042
samples (all blood-extracted) were genotyped at the
WTCRF Genetics Core with the Illumina Human610-
Quadv1 chip. These samples were then subjected to thehology, The University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ,
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quality control procedures described below, and 1005 sam-
ples remained. Of these 1005 samples, 989 had aPTT
measurements, and all further descriptions and analyses
are based on these 989 samples. The mean age of these
989 samples was 69.53 (SD ¼ 0.85, range ¼ 3.69 years).
Of the 550 individuals in the LBC1921, genomic DNA
was isolated from whole blood from 542 samples by stan-
dard procedure at Medical Research Council Technology,
Western General Hospital, Edinburgh. Sixteen samples
failed quality control preceding the genotyping procedure.
The remaining 526 samples were genotyped by theWTCRF
Genetics Core with the Illumina Human610-Quadv1 chip.
These samples were then subjected to the quality-control
procedures described below, and 517 samples remained.
Of these 517 samples, 488 participants had aPTT data avail-
able. The mean age of the participants with both genotype
and phenotype information in LBC1921 was 79.05
(SD ¼ 0.57, range ¼ 2.86 years).
Quality control of the data was performed. Individuals
with a disagreement between genetic and reported gender
were removed (n ¼ 12 in LBC1936; n ¼ 1 in LBC1921).
Relatedness between subjects was investigated and,
for any related pair of individuals, one was removed
(PI_HAT [proportion of identity by descent] > 0.25; n ¼ 8
in LBC1936; n ¼ 1 in LBC1921). Samples with a call
rate % 0.95 (n ¼ 16 in LBC1936; n ¼ 5 in LBC1921) and
those showing evidence of non-European descent bymulti-
dimensional scaling were also removed (n¼ 1 in LBC1936;
n ¼ 2 in LBC1921). SNPs were included in the analyses if
they met the following conditions: call rateR 0.98, minor
allele frequencyR 0.01, and Hardy-Weinberg equilibrium
test with pR 0.001. The ﬁnal number of SNPs included in
the genome-wide association study was 542,050.
The quantitative trait aPTT showed a normal distribu-
tion and is described in Table S1, available online. aPTT
was adjusted for the effects of gender and age in days,
because these are signiﬁcant factors in aPTT.3–5 In Figure S1,
the quantile-quantile plots for both the LBC1936 and
LBC1921 together and separately showed no evidence of
population stratiﬁcation. The lambda values suggest no
inﬂation of association signals in accordance with ran-
dom expectation (joint l ¼ 0.9976; LBC1936 l ¼ 1.004;
LBC1921 l ¼ 1.0092). Linear regression analysis covarying
for cohort effect under an additive genetic model was per-
formed with PLINK version 1.06.9 Analysis was also per-
formed removing individuals with the following criteria:
taking warfarin medication, abnormal lymphocyte count
(>103 109/L), low platelets (<1503 109/L), high platelets
(>450 3 109/L), hemophilia, leukemia, or chronic liver
disease (n ¼ 62 in LBC1936; n ¼ 45 in LBC1921). These
exclusions included aPTT outliers (Z > 5 3.4; n ¼ 3 in
LBC1936; n ¼ 3 in LBC1921). The results were viewed
with WGAViewer.10 One SNP (rs1801020) was imputed
with high conﬁdence (R2 ¼ 0.87 in LBC1936; R2 ¼ 0.85
in LBC1921) with MACH.11 Associations were reported as
genome-wide signiﬁcant (p < 108). Pairwise interaction
analysis was performed for the top, signiﬁcantly-associatedThe Amthree SNPs with the additive by additive epistasis model in
PLINK. To test for gender difference in the SNP associations
with aPTT, we carried out a quantitative trait interaction
test with PLINK. To correct for multiple testing in our
gene-based search for associations based on Figure S3, we
used a set-based permutation approach in PLINK.
Prediction of LBC1921 aPTT phenotype was performed
with the beta weights from the best SNP in each of the
genes associated with aPTT in the LBC1936 sample. They
were entered as independent variables in a linear regres-
sion model to predict aPTT values in LBC1921. The result-
ing beta weights and constant were applied to the SNPs in
LBC1921 to predict aPTT values. This analysis was per-
formed in PASW Statistics 17.0. Pathway analysis was per-
formed with STRING.12
Bioinformatic analyses were performed to predict
whether the amino acid substitution affects protein
structure and function based on sequence homology and
the physical properties of amino acids with SIFT and
PolyPhen.13,14
We identiﬁed highly signiﬁcant associations of relatively
large effect size between aPTT and SNPs in three genes: F12
(MIM *610619), KNG1 (MIM *612358) and HRG (MIM
*142640) (Table 1; Figure 1A). The strongest association
was rs2731672 (p ¼ 2.16 3 1030), an intergenic SNP
~5.8 kb upstream of the gene for coagulation factor XII
(F12), as illustrated in Figure 1B. The effects of rs2731672
on aPTT were additive, with each A allele increasing aPTT
by 0.45 SD. The SNP explained 9.6% and 6.6% of the
variation in aPTT in LBC1936 and LBC1921, respectively.
The strongest KNG1 association was with rs710446
(p ¼ 9.52 3 1022), a nonsynonymous coding SNP
(1742T>C, Ile581Thr) in exon 10 of kininogen 1 isoform 1
(high molecular weight kininogen, HMWK) (Table 1; Fig-
ure 1C). The effects of rs710446 were additive, with each
G allele decreasing aPTT by 0.36 SD. The SNP explained
5.2% and 8.1% of the variance in LBC1936 and
LBC1921, respectively. An association was also revealed
with rs9898 (p ¼ 1.34 3 1011), a nonsynonymous coding
SNP (610C>T, Pro204Ser) in exon 5 of the gene HRG, for
histidine-rich glycoprotein (HRGP). The effects were addi-
tive, with each T allele decreasing aPTT by 0.26 SD. The
SNP explained 1.8% and 0.77% of the variance in aPTT
in LBC1936 and LBC1921, respectively (Table 1; Fig-
ure 1D). There was no evidence for pairwise interactions
between the three signiﬁcant SNPs: rs9898 and rs710446
(p ¼ 0.044), rs9898 and rs2731672 (p ¼ 0.14), and
rs710446 and rs2731672 (p ¼ 0.40).
Figure S2 shows that the genetic effects of the most sig-
niﬁcantly associated SNPs in the three genes—rs2731672
(F12), rs710446 (KNG1), and rs9898 (HRG)—were additive
in both LBC1936 and LBC1921. There was a marginally
signiﬁcant effect of dominance deviation in rs2731672
(p ¼ 0.021) and rs9898 (p ¼ 0.024).
There was no evidence for SNP by gender interactions for
the three signiﬁcant SNPs (all p > 0.1). The genetic associ-
ation results separated by gender are shown in Table S2.erican Journal of Human Genetics 86, 626–631, April 9, 2010 627
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628 The American Journal of Human Genetics 86, 626–631, April 9, 2The results did not materially change after exclusion of
individuals with potentially abnormal aPTT (Table S3).
Beyond association, we showed that, by using the best
SNP in each of the three genes associated with aPTT in
LBC1936—rs2731672 (F12), rs710446 (KNG1), and
rs9898 (HRG)—and their estimated effect sizes, the aPTT
phenotype in LBC1921 can be predicted (Figure 2). The
Pearson correlation between the values predicted with
only the information about the three SNPs and actual
aPTT values was r ¼ 0.426 (p ¼ 1.29 3 1022). The regres-
sion coefﬁcient (slope) was 0.991 (standard error [SE] ¼
0.096), indicating that the prediction was unbiased.
Furthermore, we show that F12, KNG1, and HRG form
part of the same signaling pathway (Figure S3). Of the
ten pathway members, F11 (MIM *264900) showed associ-
ation with aPTT. Using a gene-based approach, we found
signiﬁcant evidence for three independently associated
SNPs (empirical set-based p ¼ 0.0005) out of nine F11
SNPs: an intronic SNP rs4253399 (nominal p¼ 1.83 105),
rs3822058 (nominal p ¼ 0.00010), and rs5971 (nominal
p ¼ 0.022).
For the two nonsynonymous SNP associations in KNG1
and HRG, prediction analysis was undertaken to estimate
the effect of SNP variability on protein structure and func-
tion. The nonsynonymous change in Kininogen-1 protein
(HMWK) (1742T>C, Ile581Thr) was predicted to be
damaging with PolyPhen analysis (score ¼ 1.557, where
score > 1.3 indicates a hydrophobicity change) but toler-
ated with SIFT analysis (score ¼ 0.66). There was no pre-
dicted effect of missense mutation in HRGP (610C>T,
Pro204Ser) because the residue was predicted to be benign
with Polyphen (score ¼ 0.102) and tolerated with SIFT
(score ¼ 0.73). To extend beyond bioinformatical predic-
tive analysis, experimental work to measure the effect of
the nonsynonymous changes on the protein’s structure,
stability, or function is necessary.
We identiﬁed genome-wide signiﬁcant associations of
relatively large effect size between the quantitative trait
of aPTT and variants in three genes, F12, KNG1, and
HRG, that all have important functional roles in the blood
coagulation cascade. The F12 gene encodes the coagula-
tion factor XII precursor. Factor XII is a plasma glycopro-
tein that participates in the initiation of blood coagulation,
activation of the kallikrein-kinin system, ﬁbrinolysis, and
the generation of bradykinin (encoded by KNG1) and
angiotensin. Factor XII is a known determinant of aPTT.
Here we report association of SNPs in this genomic region
with aPTT, which may reﬂect the inﬂuence of F12 on aPTT.
Our strongest associated SNP, rs2731672, correlates highly
with the F12 46C>T polymorphism (rs1801020, R2 ¼ 0.87
CEU HapMap), which has been associated with FXII
levels,15 risk of thrombosis including ischemic stroke16
(MIM #601367), and venous thrombosis.17 Analysis of
our imputed data also shows a highly signiﬁcant associa-
tion with rs1801020 in a joint analysis (R2 ¼ 0.077,
p ¼ 1.24 3 1027) and separately in both cohorts,
LBC1936 (R2 ¼ 0.088, p ¼ 2.3 3 1021) and LBC1921010
Figure 1. Genomic Overview of the Significant Regions Associated with Activated Partial Thromboplastin Time
(A) Associations were determined for 542,050 SNPs in two cohorts: the Lothian Birth Cohort 1936 (LBC1936; n ¼ 989) and the Lothian
Birth Cohort 1921 (LBC1921; n ¼ 488). The x axis represents the position of each chromosome from the p terminus to the q terminus.
The y axis depicts p values (-log10(P)). The y axis is truncated at 14: points above this line are placed at the top of the graph and are indi-
cated with arrows and text. Red dots indicate SNPs that surpassed the genome-wide signiﬁcance threshold (p < 108).
(B–D) The genotyped SNPs in the region of signiﬁcance, the location of surrounding genes (HRG, KNG1, and F12, respectively), and the
linkage disequilibrium in the region (HapMap CEU) are shown.(R2 ¼ 0.060, p ¼ 4.7 3 108) (Figure S2). The A allele (cor-
responding to the T allele of the 46C>T polymorphism) is
associated with an increase in aPTT (prolonged aPTT). This
is not the expected biological direction of effect, because
a decrease in aPTT (and ratio) is associated with thrombotic
diseases.3 However, other prothrombotic phenotypes and
coagulation deﬁciencies, such as lupus anticoagulants,
are associated with prolongation (not shortening) of the
aPTT in vitro.
The secondmajor aPTTassociation was with isoform 1 of
KNG1, which encodes HMWK. HMWK plays an important
role in blood coagulation by positioning prekallikrein
and factor XI near factor XII. Defects in KNG1 are the cause
of HMWK deﬁciency (MIM #228960), which is an auto-
somal recessive coagulation defect. KNG1 gene variants
are associated with essential hypertension and blood pres-
sure in the Chinese Han population in a gender-speciﬁc
manner18 and have a consistent effect on aldosterone
response to antihypertensive drug therapy.19 KNG1 knock-
out mice demonstrate prolonged aPTT and delayed arterial
thrombosis.20 Because KNG1 is also associated with blood
pressure in the Chinese Han population, we attempted to
replicate the ﬁndings in the LBC1921 and LBC1936
cohorts. Genotype data for the same SNPs reported in Mer-
kulov et al.20 were available (rs1851665, rs2304456,
rs4686799, and rs5030062). We found no association at
the single SNP or haplotype level to sitting and standingThe Amsystolic and diastolic blood pressures with an Omron
705IT monitor (all p values > 0.05) (further details avail-
able upon request).
The third major association with aPTT was with HRG,
which encodes a histidine-rich glycoprotein that is located
in plasma and platelets. HRG can inhibit rosette formation
and interacts with heparin, thrombospondin, and plas-
minogen (as reviewed in 21). HRG’s effect on the inhibition
of ﬁbrinolysis and the reduction of inhibition of coagula-
tion indicates a potential prothrombotic effect. Mutations
in this gene lead to thrombophilia, detected by prolonged
aPTT (MIM *142640).
A suggestive association of F11with aPTTwas also found.
F11 variants have been associated with deep vein throm-
bosis.22 Defects in coagulation factor XI (MIM #612416)
lead to Rosenthal syndrome, a blood coagulation abnor-
mality,23,24 and hypertension induced by pregnancy.24
We have identiﬁed single variants in three genes that
account for ~18% of the variance of aPTT. These three
genes are implicated in the coagulation cascade, but their
relative functional importance has yet to be established.
Heritability estimates suggest that there are further contri-
butions to aPTT’s genetic variability to be discovered. The
variants reported here account for a relatively substantial
proportion4,5 of normal variation in aPTT in two age-
homogeneous, ethnically homogeneous, and geographi-
cally homogeneous samples. The true effect sizes of theerican Journal of Human Genetics 86, 626–631, April 9, 2010 629
Figure 2. Prediction of the Lothian Birth Cohort 1921 Activated
Partial Thromboplastin Time Phenotype
The estimated effect sizes from the best SNP in each of the three
genes associated with aPTT in the LBC1936 sample—rs2731672
(F12), rs710446 (KNG1), and rs9898 (HRG)—were used. They
were entered as independent variables in a linear regressionmodel
to predict aPTT values in LBC1921. The resulting regression coef-
ﬁcients were applied to the SNPs in LBC1921 to create a genetic
predictor of aPTT for each person. Here, observed aPTT values
are plotted against these predicted values. The observed values of
aPTT correlate with their predictions (Pearson correlation ¼
0.426; R2 ¼ 0.181, p ¼ 1.3 3 1022). The regression coefﬁcient
(slope) was 0.991 (SE ¼ 0.096), indicating that the prediction
was unbiased. The y axis was truncated at 3.5, removing three
samples from the ﬁgure. aPTT values are standardized variables,
having been adjusted for age and sex.real functional variants may be even greater. Further exper-
imental studies are required to establish the mechanisms
by which these three genes prolong the aPTT in vitro
and inﬂuence thrombosis in vivo.Supplemental Data
Supplemental Data include three ﬁgures and three tables and can
be found with this article online at http://www.ajhg.org.Acknowledgments
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